EntryPoint Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

EntryPoint Capital’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-53,745	Closed	-$171K	–	654
2025 Q1	$171K	Sell	53,745 -62,900	-54%	-$296K	0.08%	568
2024 Q4	$624K	Buy	+116,645	New	+$871K	0.26%	48

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EntryPoint Capital's CRVS Position: Q2 2025 in Review

EntryPoint Capital sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 53,745 shares — an estimated $171K sold.

EntryPoint Capital first reported a position in CRVS in Q4 2024 and held it in 2 quarters. The position peaked at $624K in Q4 2024. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

EntryPoint Capital reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
EntryPoint Capital sold 53,745 Corvus Pharmaceuticals shares in Q2 2025, an estimated $171K.
EntryPoint Capital first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 2 quarters.
EntryPoint Capital's Corvus Pharmaceuticals position peaked at $624K in Q4 2024.
92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on EntryPoint Capital's 13F filing for Q2 2025, filed 11 Aug 2025.